Proactive Investors - Run By Investors For Investors

4D Pharma’s Blautix “safe and well-tolerated”

The pharmaceutical firm has successfully completed phase I clinical trials for its IBS treatment Blautix
A scientist testing some samples in a lab
Phase I trials typically only assess the safety of a new drug and not its effectiveness

Biotherapeutics firm 4D Pharma PLC (LON:DDDD) Irritable Bowel Syndrome (IBS) treatment, Blautix has passed a phase I clinical trial.

“We have shown Blautix to be safe and well tolerated,” said chief executive Duncan Peyton.

“This trial is providing patient samples that will give the company a better understanding of what is happening in IBS patients undergoing the treatment of Blautix.”

4D is now analysing the samples and data from the trials in greater detail to help develop its understanding of Blautix and to help design the next round of trials.

Phase I trials assess the safety of the drug. The next stage, phase II, is the first test of a new treatment’s efficacy.

Shares rose 19.5p or 2.4% to 850p.

View full DDDD profile View Profile

4D Pharma Timeline

Newswire
June 10 2016

Related Articles

young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
cancer
11:30
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use